Florida Administrative Code
64 - DEPARTMENT OF HEALTH
64B16 - Board of Pharmacy
Chapter 64B16-26 - PHARMACISTS LICENSURE
Section 64B16-26.304 - Subject Matter for Nuclear Pharmacist License Renewal Continuing Education Programs
Universal Citation: FL Admin Code R 64B16-26.304
Current through Reg. 50, No. 187; September 24, 2024
(1) A licensee completing the continuing education requirement for nuclear pharmacist license renewal pursuant to Rule 64B16-26.103, F.A.C., shall complete twenty-four (24) additional hours per biennium of coursework each two year period by or through a Committee approved provider, instructionally designed to provide in-depth treatment of nuclear pharmacy practice with suggested subject matter set out in subsection (2), of this rule.
(2) Content of nuclear pharmacist continuing education program.
(a) Application of
radiopharmaceutical theory in a practice or a research setting with respect to
the drug products and their clinical application. Provision of drug and
radiopharmaceutical information as it pertains to optimal handling and use of
these products in a clinical setting.
(b) Effective communication skills in a
multi-disciplinary environment with patients, nuclear medicine physicians,
nuclear medicine technologists, radiation safety personnel and other nuclear
pharmacists. The multi-faceted regulatory environment requires such skills in
the preparation and maintenance of a radioactive by-product materials license,
the identification and reporting of adverse reactions and misadministration,
instances of poor product performance, environmental and personnel radiation
safety.
(c) Application of the most
rigorous and up-to-date principles of radiation safety and quality assurance in
order to assure regulatory compendia, and operational standards for drug and
radiopharmaceutical products and equipment. Recordkeeping and other
documentation activities essential to procurement, storage, compounding,
handling and use, distribution and disposal should be emphasized.
(d) Management of a nuclear pharmacy unit in
accordance with regulatory and administrative agencies' requirements.
(e) Advances in drug, radiopharmaceutical or
related technology (including, but not limited to: monoclonal antibodies,
magnetic resonance imaging, computed tomography, positron-emission tomography,
radioplaque and other contact enhancement agents, radioimmunoassay) with
emphasis on paragraphs (a)-(d), above, for such new
agents.
Rulemaking Authority 465.005, 465.0126 FS. Law Implemented 465.0126 FS.
New 1-18-05.
Disclaimer: These regulations may not be the most recent version. Florida may have more current or accurate information. We make no warranties or guarantees about the accuracy, completeness, or adequacy of the information contained on this site or the information linked to on the state site. Please check official sources.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.